Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05678673 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT05678673 · ClinicalTrials.gov record · last posted 2026-07-29

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Name: Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma — clinical trial record (NCT05678673)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: STELLAR-304

StatusActive, Not Recruiting

PhasePhase 3

SponsorExelixis

Started2023-01-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a multicenter, randomized (2:1), open-label, controlled Phase 3 trial of XL092 in combination with nivolumab versus sunitinib in subjects with unresectable, locally advanced or metastatic nccRCC who have not received prior systemic anticancer therapy.

Protocol amendment history 1 change detected by DataLookout

2026-07-30

Primary completion pushed: 2025-07 → 2026-12-15

Trial Details

NCT Number	NCT05678673
Lead Sponsor	Exelixis
Conditions	Non-Clear Cell Renal Cell Carcinoma
Enrollment	317 participants
Start Date	2023-01-01
Primary Completion	2026-12-15 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-29